This study aims to see if a drug called Debio 4326 can help children with a condition known as Central Precocious Puberty (CPP). CPP is when a child's body starts developing adult features too early. Children in the study are already getting a type of medicine called GnRHa therapy to help manage CPP. The study will last for 52 weeks (about a year) and will look at how good Debio 4326 is at keeping a hormone called luteinizing hormone (LH) at low levels, like in younger kids. LH is important because it can cause the body to start growing and changing.

• Participation involves at least one year of treatment.
• Eligibility includes specific age and puberty signs, with restrictions on other conditions.
• Requires regular monitoring and no prior use of certain medicines.